Cardiome Pharma Corp. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017; Provides Revenue Guidance for the Year 2018
For the six months, the company reported revenue was $10,953,000 against $13,001,000 a year ago. Operating loss was $11,877,000 against $5,632,000 a year ago. Loss before income taxes was $14,814,000 against $8,611,000 a year ago. Net loss was $14,845,000 against $8,748,000 a year ago. Loss per common share - diluted was $0.46 against $0.46 a year ago. Net cash used in operating activities was $14,104,000 against $6,851,000 a year ago. Purchase of property and equipment was $5,000 against $9,000 a year ago. Purchase of intangible assets was $13,000 against $5,611,000 a year ago.
The company expects meaningful revenues to begin in 2018.